Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meribank Biotech Co Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Meribank Biotech Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4724 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, Meribank Biotech Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meribank Biotech Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Meribank Biotech Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meribank Biotech Co (ROCO:4724) has a Buyback Yield % of -12.88 as of Aug. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Meribank Biotech Co and its competitors. According to the industry distribution chart, Meribank Biotech Co ranks #415 out of 735 companies in the Biotechnology industry, placing it in the top 56.5%.
Is Meribank Biotech Co's Buyback Yield % too high?
Meribank Biotech Co's current Buyback Yield % is -12.88. Based on the distribution chart, Meribank Biotech Co ranks #415 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Meribank Biotech Co has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Meribank Biotech Co ranks #415 out of 735 companies for Buyback Yield %. This places Meribank Biotech Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Meribank Biotech Co and its competitors. Meribank Biotech Co's current Buyback Yield % is -12.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$49.24, compared to a current price of NT$9.35 — trading 81% below its estimated fair value. The current Buyback Yield % is -12.88. Meribank Biotech Co's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current Buyback Yield % is -12.88 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?
Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued.
The current stock price of NT$9.35 is trading 81% below its estimated GF Value™ of NT$49.24.
GuruFocus considers Meribank Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4724:
Buyback Yield %: -12.88
GF Value™: NT$49.24 vs. price of NT$9.35 (81% below fair value)
No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
38GF Score
Get the complete analysis for ROCO:4724
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4724 has been successfully added to your 
